Add-on omalizumab cost effective in uncontrolled allergic asthma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 30, 2019 Category: Drugs & Pharmacology Source Type: news
Omalizumab: A Potential Therapy Option for Allergic Bronchopulmonary Aspergillosis (ABPA) in Asthma Patients
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Clinical trial to evaluate experimental treatment in people allergic to multiple foods
NIH and partners to assess whether Omalizumab can reduce allergic reactions. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 1, 2019 Category: American Health Source Type: news
Xolair (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
Roche today announced positive topline data from two Phase III multicenter studies evaluating Xolair ® (omalizumab) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to intranasal corticosteroids. (Source: Roche Investor Update)
Source: Roche Investor Update - June 3, 2019 Category: Pharmaceuticals Source Type: news
Economics of omalizumab responder identification in asthma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2019 Category: Drugs & Pharmacology Source Type: news
In Chronic Urticaria, Staying on Treatment Matters
(MedPage Today) -- 55% of patients who stopped taking omalizumab saw return of symptoms (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 27, 2019 Category: Primary Care Source Type: news
Omalizumab add-on therapy cost effective in severe asthma in Spain
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news
Novartis receives European Commission approval for self-administration of Xolair ® across all indications
Novartis today announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment. With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU. (Source: World Pharma News)
Source: World Pharma News - December 13, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Novartis's New Treatment for Hives Outperforms Xolair in Trials Novartis's New Treatment for Hives Outperforms Xolair in Trials
Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 7, 2018 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Novartis's new treatment for hives outperforms Xolair in trials
Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives. (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Novartis goes after Roche asthma medicine Xolair with new drug
Novartis said it is pushing ahead with a late-stage study of its experimental drug ligelizumab after announcing the medicine outperformed Roche's Xolair in a Phase II clinical trial against urticaria, also known as hives. (Source: Reuters: Health)
Source: Reuters: Health - December 4, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Omalizumab Seems Safe, Effective for Real-World Chronic Idiopathic Urticaria Omalizumab Seems Safe, Effective for Real-World Chronic Idiopathic Urticaria
In real-world patients with chronic idiopathic urticaria (CIU), omalizumab meets or exceeds the safety and efficacy results seen in clinical trials, researchers say.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 27, 2018 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Omalizumab Effective Rescue Therapy for Status Asthmaticus Omalizumab Effective Rescue Therapy for Status Asthmaticus
Omalizumab can be effective as rescue therapy for refractory status asthmaticus related to pollen allergy, a case report suggests.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 21, 2018 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news
Omalizumab Treatment in Patients with Cystic Fibrosis (CF) and Allergic Bronchopulmonary Aspergillosis (ABPA): a Case Series
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 16, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news
Cost-Effectiveness of Omalizumab for Chronic Urticaria Cost-Effectiveness of Omalizumab for Chronic Urticaria
How cost-effective is omalizumab compared with standard of care with antihistamines?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 5, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
